A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5864399 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Selected Advanced Solid Tumours
This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:US GSK Clinical Trials Call Center
- 電話番号:877-379-3718
- メール:GSKClinicalSupportHD@gsk.com
研究連絡先のバックアップ
- 名前:EU GSK Clinical Trials Call Center
- 電話番号:+44 (0) 20 89904466
- メール:GSKClinicalSupportHD@gsk.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Is at least 18 years of age or the legal age of consent.
-
Has histologically confirmed unresectable metastatic disease of either:
- colorectal cancer that has progressed through at least 2 prior lines of systemic therapy
- non-small cell lung cancer that has progressed through at least 1 prior line of systemic therapy
-
Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
-
Participants must provide Formalin-Fixed, Paraffin-Embedded (FFPE) tumour tissue sample taken from primary cancer or metastatic site.
-
Is willing to use adequate contraception.
-
Is capable of giving signed informed consent.
-
Has an ECOG performance status of 0 or 1.
-
Has adequate organ function.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria
-
Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months (with some exceptions).
-
Has had any major surgery within 28 days prior to first dose.
-
Has any history of prior allogeneic or autologous bone marrow transplant or other solid organ transplant.
-
Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
-
Has known active infectious disease or a serious infection within 4 weeks prior to the first dose.
-
Has a history (in prior year) of clinically significant or uncontrolled cardiovascular disease.
-
Has untreated brain or Central Nervous System (CNS) metastases or brain/CNS metastases that have progressed.
-
Any evidence of small cell or sarcomatoid histology for the NSCLC participants.
-
Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
-
Has any active renal condition.
-
Has a history of discontinuing prior treatment due to TEAE of ILD/pneumonitis
-
Has a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis that required active treatment within 4 weeks before study-intervention administration.
-
Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy (with some exclusions).
-
Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.
-
Has symptomatic and/or progressive pleural metastases or cytologically confirmed malignant pleural effusions despite appropriate analgesia and thoracenteses respectively. Participants with previously treated pleural metastases/malignant pleural effusions with clinical stability demonstrated for at least 4 weeks prior to first dose are not excluded from participation.
-
Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long term [30 days or longer]).
-
Has received any prior therapy targeting CEACAM5.
-
Has received any live vaccine within 30 days of first dose. Vaccination against COVID-19 using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary. Messenger Ribonucleic acid (mRNA) and adenoviral-based COVID-19 vaccines are considered non-live. If a COVID-19 vaccine is administered at any time, the date of COVID-19 vaccination must be entered in the electronic Case Report Form (eCRF).
-
Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before first dose.
-
History of local radiotherapy within 2 weeks prior to the first dose of study intervention; more than 30% of bone marrow irradiation or extensive radiotherapy within 4 weeks before the first dose of study intervention.
-
Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent within 4 weeks prior to first dose. Participation in study follow-up part without IMP administration, non-interventional registry or epidemiological study is allowed.
-
Has a known Human Immunodeficiency Virus (HIV) infection AND meets at least one of the following criteria:
- Has documented evidence of plasma HIV-1 Ribonucleic Acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
- Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
- Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
- Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in full protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
- Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
- Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening. Participants with history of CDC Stage 3 disease (also known as AIDS defining disease are eligible provided all other applicable criteria are met) if the AIDS-defining disease has been treated and cured or is stable for at least 3 months prior to screening. Cutaneous Karposi's Sarcoma not requiring systemic therapy is not exclusionary.
-
Is unable to adhere to the protocol-defined schedule of assessments, including requirements for the follow-up period of the study.
-
Has an Alanine Aminotransferase (ALT) or AST value >2.5x Upper Limit of Normal (ULN) and/or for participants with documented liver metastases/tumour infiltration has an ALT or AST value >5x ULN.
-
Has a total bilirubin value >1.5x ULN. Participants with Gilbert's syndrome can be included with a total bilirubin value >1.5x ULN, provided direct bilirubin is ≤1.5x ULN and participant otherwise meets entry criteria.
-
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Stable noncirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if the participant otherwise meets entry criteria.
-
Has documented presence of Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention. In Japan, the following modification is applied; Has documented presence of HBsAg, HBcAb, or Hepatitis B surface antibody (HBsAb) (except for presence of HBsAb attributable to previous vaccination) at screening or within 3 months prior to the first dose of study intervention. For participants with presence of HBsAb, Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) will be tested every 3 months.
-
Has a positive Hepatitis C Virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV RNA is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment. Participants with a positive HCV antibody test result due to prior resolved disease, including those who have undergone curative HCV treatment, can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria.
-
Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention. The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
-
Has baseline QT interval corrected for heart rate (QTc)>480 msec.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:パート 1: 用量漸増
|
GSK5864399 will be administered |
|
実験的:パート 2: 用量の拡大
|
GSK5864399 will be administered |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with changes in safety parameters
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severity
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with AEs leading to dose modifications
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with a change from baseline in body weight
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
時間枠:Up to approximately 155 weeks
|
Up to approximately 155 weeks
|
|
|
Part 2: Confirmed Objective Response Rate (cORR)
時間枠:Up to approximately 155 weeks
|
cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1. |
Up to approximately 155 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1& 2: Maximum concentration (Cmax) of GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
|
|
Part 1& 2: Time to maximum concentration (Tmax) of GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
|
|
Part 1& 2: Area under the concentration-time curve (AUC) of GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
|
|
Part 1& 2: Trough concentration (Ctrough) of GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
|
|
Part 2: Progression-free survival (PFS)
時間枠:Up to approximately 161 weeks
|
PFS is defined as the time from date of randomization until the earliest date of documented disease progression as assessed by the Investigator according to RECIST1.1 or death due to any cause. |
Up to approximately 161 weeks
|
|
Part 2: Duration of Response (DoR)
時間枠:Up to approximately 161 weeks
|
DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by the Investigator according to RECIST1.1) until the date of the first documented progression of disease (PD) or death, whichever is earlier. |
Up to approximately 161 weeks
|
|
Part 1 & 2: Number of participants with Anti-drug antibodies (ADA) against GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
|
|
Part 1 & 2: Titers of ADA against GSK5864399
時間枠:Up to approximately 161 weeks
|
Up to approximately 161 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 308367
- 2026-527385-67 (その他の識別子:EU CT Number)
- 2026-527385-67 (レジストリ識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。